Listed by the USPTO as SMALL, KATHERINE R
Tech Center 1600 • Art Units: 1633
This examiner grants 69% of resolved cases
SMALL, KATHERINE R works in Tech Center 1600 and Art Unit 1633. She has 62 resolved cases, with a 69.4% allowance rate and a 29.6% interview lift. The median time to allowance is 1422 days.
Her listed companies are University of Florida Research Foundation Inc., Intellia Therapeutics Inc., and Massachusetts Institute of Technology. Her listed firms are Berg Hill Greenleaf & Ruscitti LLP, HULTQUIST IP, and Johnson, Marcou, Isaacs & Nix, LLC. The interview lift is a notable feature of this limited-volume record and may support considering interviews in prosecution planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18692493 | AAV PARTICLES WITH MODIFIED INVERTED TERMINAL REPEATS FOR ENHANCED GENE EXPRESSION IN MUSCLE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | Non-Final OA | Intellia Therapeutics, Inc. |
| 17638355 | CRISPR-ASSOCIATED MU TRANSPOSASE SYSTEMS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18625740 | HUMAN CEREBELLAR ORGANOIDS WITH BONA FIDE PURKINJE CELLS AND USES THEREOF | Non-Final OA | University of Southern California |
| 18711487 | METHOD FOR ISOLATING, MAINTAINING, PROLIFERATING, AND DIFFERENTIATING MONOCLONAL CELLS DERIVED FROM HUMAN SALIVARY GLAND EPITHELIAL STEM CELLS OR PROGENITOR CELLS AND PRODUCTION METHOD FOR EXTRACELLULAR VESICLES FOR TREATING SALIVARY GLAND DISEASES | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18474697 | SYSTEMS AND METHODS FOR EXOSOME DELIVERY OF MICRORNAS FOR CELLULAR REPROGRAMMING | Final Rejection | Duke University |
| 18037945 | LIGHT-CONTROLLED VIRAL TRANSDUCTION | Final Rejection | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG |
| 18569736 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | RACTHERA Co., Ltd. |
| 17738584 | INDUCTION OF TUMOR VASCULAR NECROSIS UTILIZING FIBROBLASTS | Final Rejection | FibroBiologics |
| 17266592 | Homologous Recombination Reporter Construct and Uses Thereof | Final Rejection | NemaMetrix, Inc |
| 17784740 | METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION | Non-Final OA | Jeong Chan RA |
| 17603276 | Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins | Non-Final OA | Nature's Toolbox, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy69.4% of resolved applications examined by Katherine R Small were allowed (62 resolved cases), compared with 34.8% across Art Unit 1633 over the last five years.
This examiner's interview lift is +29.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Katherine R Small took 1,422 days on average from filing to allowance.
Katherine R Small examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
